SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01789060

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

NCT01789060 Malignant Lymphoma P13K-AKT Pathway Deregulation
MeSH:Lymphoma
HPO:Lymphoma

1 Interventions

Name: p-AKT immunohistochemical staining

Description: p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
Type: Other
Group Labels: 1

p-AKT


Primary Outcomes

Measure: Difference of overall survival according to p-AKT status in malignant lymphoma

Time: study entry

Secondary Outcomes

Measure: Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)

Time: study entry

Other Outcomes

Measure: Subgroup analysis of overall survival according to International Prognostic Index risk groups

Time: study entry

Time Perspective: Retrospective

Cohort


There is one SNP

SNPs


1 P13K

Primary central nervous system lymphoma was excluded in this study Malignant Lymphoma P13K-AKT Pathway Deregulation Lymphoma Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. --- P13K ---



HPO Nodes


HPO: